These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17076680)

  • 1. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract.
    Keller MJ; Herold BC
    Am J Reprod Immunol; 2006; 56(5-6):356-63. PubMed ID: 17076680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical microbicides for the prevention of genital herpes infection.
    Keller MJ; Tuyama A; Carlucci MJ; Herold BC
    J Antimicrob Chemother; 2005 Apr; 55(4):420-3. PubMed ID: 15743896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections.
    Nikolic DS; Garcia E; Piguet V
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):77-88. PubMed ID: 17266456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the local microenvironment in regulating susceptibility and immune responses to sexually transmitted viruses in the female genital tract.
    Kaushic C
    J Reprod Immunol; 2009 Dec; 83(1-2):168-72. PubMed ID: 19857903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing transmission: plant-derived microbicides and mucosal vaccines for reproductive health.
    Whaley KJ; Zeitlin L
    Vaccine; 2005 Mar; 23(15):1819-22. PubMed ID: 15734048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.
    Anjuère F; Bekri S; Bihl F; Braud VM; Cuburu N; Czerkinsky C; Hervouet C; Luci C
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():117-22. PubMed ID: 22882377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment.
    Kaushic C; Ferreira VH; Kafka JK; Nazli A
    Am J Reprod Immunol; 2010 Jun; 63(6):566-75. PubMed ID: 20384619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission.
    Kaul R; Pettengell C; Sheth PM; Sunderji S; Biringer A; MacDonald K; Walmsley S; Rebbapragada A
    J Reprod Immunol; 2008 Jan; 77(1):32-40. PubMed ID: 17395270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
    J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
    Roberts L; Liebenberg L; Barnabas S; Passmore JA
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):441-9. PubMed ID: 22429786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection.
    Dhawan D; Mayer KH
    J Infect Dis; 2006 Jan; 193(1):36-44. PubMed ID: 16323129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.
    Herold BC; Mesquita PM; Madan RP; Keller MJ
    Am J Reprod Immunol; 2011 Mar; 65(3):325-33. PubMed ID: 21143689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual action microbicides: reappraisal of their roles in contraceptive research.
    Chandran P; Kabir SN
    Reprod Biomed Online; 2010 Jan; 20(1):103-13. PubMed ID: 20158995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Female genital tract immunity: distinct immunological challenges for vaccine development.
    Naz RK
    J Reprod Immunol; 2012 Jan; 93(1):1-8. PubMed ID: 22154945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical microbicides for disease prevention: status and challenges.
    Harrison PF; Rosenberg Z; Bowcut J
    Clin Infect Dis; 2003 May; 36(10):1290-4. PubMed ID: 12746775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
    van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
    Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
    Mestecky J
    J Reprod Immunol; 2006 Dec; 72(1-2):1-17. PubMed ID: 17095369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbicides: a new approach to preventing HIV and other sexually transmitted infections.
    Stone A
    Nat Rev Drug Discov; 2002 Dec; 1(12):977-85. PubMed ID: 12461519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance and protection against infection in the genital tract.
    Russell MW; Mestecky J
    Immunol Invest; 2010; 39(4-5):500-25. PubMed ID: 20450289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
    Keller MJ; Guzman E; Hazrati E; Kasowitz A; Cheshenko N; Wallenstein S; Cole AL; Cole AM; Profy AT; Wira CR; Hogarty K; Herold BC
    AIDS; 2007 Feb; 21(4):467-76. PubMed ID: 17301565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.